Robotic Surgery Leader 'Intuitive Surgical' Executive Sells Shares Amid Stock Weakness

On May 11, Gary Loeb, Chief Legal and Compliance Officer at Intuitive Surgical Inc. (Nasdaq: ISRG), sold 400 shares of the company’s common stock under a pre-established Rule 10b5-1 trading plan at an average price of $446.95 per share, generating approximately $179,000 in proceeds (around KRW 240 million). Following the sale, his direct holdings declined to 6,120 shares, valued at about $2.73 million (roughly KRW 3.5 billion) on the same price basis.

Earlier, on April 28–29, board member Amy L. Ladd likewise executed share sales under a Rule 10b5-1 plan, realizing approximately $292,000 (about KRW 400 million) and reducing her stake to around 120 shares after two transactions.

In the first quarter of 2026, Intuitive Surgical reported revenue of roughly $2.77 billion and adjusted earnings per share of $2.50, surpassing market expectations. Major brokerages have maintained buy ratings with price targets in the $670–$750 range.

Despite these solid results, on May 11 ISRG shares slipped into the low-$420 range—a 52-week low—as product safety concerns and valuation pressures heightened short-term volatility.

Headquartered in Sunnyvale, California, Intuitive Surgical is a global medical device company best known for its da Vinci robotic-assisted minimally invasive surgery systems. A component of the Nasdaq 100, S&P 500, and Fortune 500 indices, the company—led by CEO Gary S. Guthart—supplies robotic surgical platforms to hospitals worldwide, generating revenue from system sales as well as procedure-based fees and consumables as its installed base and procedure volume grow.